Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD [Yahoo! Finance]
Cencora, Inc. (COR)
Last cencora, inc. earnings: 4/30 06:30 am
Check Earnings Report
US:NYSE Investor Relations:
investors.coresite.com/investor-overview
Company Research
Source: Yahoo! Finance
European Commission decision applies automatically to all 27 EU Member States and, within 30 days, also to Iceland, Norway and Liechtenstein LYTENAVA™ (bevacizumab gamma) receives ten years of market exclusivity in EU Advancing toward commercial launch of LYTENAVA™ (bevacizumab gamma) in EU expected in calendar Q1 2025 Strategic partnership with Cencora (formerly AmerisourceBergen) to support the planned commercial launches of LYTENAVA in EU ISELIN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, today announced that the European Commission has granted Marketing Authorization for LYTENAVA™ (bevacizumab gamma), an ophthalmic formulation of bevacizumab for the treatment of wet AMD in the EU. LYTENAVA™ (bevacizumab gamma) is the first and only authorized ophthalmic formula
Show less
Read more
Impact Snapshot
Event Time:
COR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COR alerts
High impacting Cencora, Inc. news events
Weekly update
A roundup of the hottest topics
COR
News
- Rural Clinical and Healthcare Logistics Market Report, 2024-2028: Increased Penetration of Drones Driving the Market at a 5.84% CAGR [Yahoo! Finance]Yahoo! Finance
- Pharma giant's data breach exposes patients' sensitive information [FOX News]FOX News
- Healthcare Logistics Market size is set to grow by USD 121.4 billion from 2024-2028, Growing global pharmaceutical sales to boost the market growth, Technavio [Yahoo! Finance]Yahoo! Finance
- Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now [Yahoo! Finance]Yahoo! Finance
- Cencora Data Breach Reportedly Involving Personal and Sensitive Medical Information - COR Accesswire
COR
Earnings
- 5/1/24 - Beat
COR
Sec Filings
- 6/20/24 - Form 4
- 6/18/24 - Form 144
- 6/13/24 - Form 11-K
- COR's page on the SEC website